Global biopharmaceutical company headquartered in Cambridge, UK
Pharmaceutical leaders AstraZeneca and Bristol-Myers highlight how corporate scale and enlarged balance sheets allow major drugmakers to make larger investments in prospective blockbuster medications.
Industry analysis highlights key strategic questions surrounding AstraZeneca and BMS, including focus areas in oncology, cardiology, patent-cliff avoidance, and U.S. market expansion.
Shares of AstraZeneca fell sharply following market speculation regarding a potential mega-merger. Industry reports linked the stock decline to unconfirmed rumors of a deal involving Bristol Myers Squibb.
Pharmaceutical giant AstraZeneca reportedly held talks with rival Bristol Myers Squibb concerning a potential merger valued at $400 billion, according to a source reported by Reuters.